Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
The discovery of BRAF mutation in ~50% of melanomas led to the development of small molecule BRAF inhibitors, including sorafenib, debrafenib, and vemurafenib. Clinical trials have shown these agents to be effective in treatment of metastatic and locally advanced melanoma, increasing overall and progression-free survival. However, some of the most common toxicities associated with BRAF inhibitor therapy include adverse skin events such as rashes, photosensitivity, hyperkeratosis, papillomas, keratoacanthomas, and squamous cell carcinomas. Here, the authors describe 3 patients who developed keratinocytic neoplasms on the eyelid, including invasive squamous carcinoma secondary to vemurafenib. Vigilant screening and a high index of suspicion for eyelid carcinomas are recommended in patients treated with vemurafenib.
*Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas M.D. Anderson Cancer Center, Houston; †Department of Ophthalmology, The University of Texas Medical Branch, Galveston; and ‡Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.
Vivian T
VT
Yin
Tomasz A
TA
Wiraszka
Michael
M
Tetzlaff
Jonathan L
JL
Curry
Bita
B
Esmaeli
D000368:Aged; D002277:Carcinoma / Q000188:drug therapy; D002291:Carcinoma, Papillary; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000473:pathology; D005142:Eyelid Neoplasms / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D049488:Phosphatidylethanolamine Binding Protein / Q000009:adverse effects*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000188:drug therapy; D000077484:Vemurafenib
D007211:Indoles; C511482:PEBP1 protein, human; D049488:Phosphatidylethanolamine Binding Protein; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf